Brief: Cogent Biosciences Updated Clinical Results From Open Label Extension Portion Of Summit Trial
09/12/2024 12:16
Dec 9 (Reuters) - Cogent Biosciences Inc COGT.O :
* COGENT BIOSCIENCES: UPDATED CLINICAL RESULTS FROM OPEN
LABEL
EXTENSION PORTION OF SUMMIT TRIAL
* COGENT BIOSCIENCES: 56% MEAN IMPROVEMENT IN TOTAL SYMPTOM
SCORE
AT 24 WEEKS WITH 76% OF PATIENTS ACHIEVING AT LEAST A 50%
REDUCTION IN TSS
* COGENT BIOSCIENCES INC: TOP-LINE RESULTS NOW EXPECTED IN
JULY
2025
Source text: ID:nGNX5QcVCs
Further company coverage: COGT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cogent Biosciences
See all newsBrief: Cogent Biosciences - Enters Commercial Supply Agreement With Hovione On Sept 1, 2026 - SEC Filing
Brief: Cogent Biosciences - May Offer Up To $400 Million In Common Stock Through Guggenheim Securities
Cogent Biosciences Q2 net loss widens on higher expenses
Brief: Cogent Biosciences Q2 Net Income USD -96.405 Million
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's